Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polynovo ( (AU:PNV) ) has provided an announcement.
PolyNovo reported unaudited first-half FY26 group sales of A$68.2 million, a 26% year-on-year increase driven by strong U.S. performance and rapid growth in NovoSorb MTX, while Rest of World sales also rose sharply, offsetting an expected decline in BARDA revenue as a pivotal burn trial concluded. Total revenue including BARDA reached A$70.4 million, cash flow from operations swung to a A$9.5 million inflow, and the new manufacturing facility was completed on time and budget, underpinning future capacity, as the company advances a U.S. pre-market approval submission for full-thickness burns, seeks expanded CMS reimbursement and coding for its products, and navigates evolving U.S. outpatient skin substitute policies while meeting heightened European demand following recent mass-casualty burn events.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.03 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited is an Australia-based medical technology company that develops and commercialises the NovoSorb range of bioresorbable polymer devices for the treatment of complex wounds and burns. Its primary products, including NovoSorb BTM and NovoSorb MTX, are used in reconstructive and burn surgery, with a strong and growing presence in the U.S., Australia and other international markets, and strategic focus on hospital inpatient and emerging outpatient skin substitute markets.
YTD Price Performance: -2.03%
Average Trading Volume: 1,579,558
Technical Sentiment Signal: Sell
Current Market Cap: A$832.5M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.